Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Genes contain instructions for protein production, with the central dogma of biology stating that this information flows from ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly ...

Nobel Prize winner and UC Berkeley professor Jennifer Doudna presented developments on her gene research at a UC Santa Barbara Arts & Lectures event on Oct. 22.

Editas Medicine announced proof-of-concept data for a gene-editing approach for sickle cell disease that doesn't need a stem ...

A set of 5700 free MIT-licensed high-quality SVG icons for you to use in your web projects. Each icon is designed on a 24x24 grid and a 2px stroke.

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding ...

Labroots invites you to the 7th Annual Event in the CRISPR Virtual Event Series 2024 taking place on October 23rd, 2024! This event will continue the conversation of the abilities of CRISPR-based ...